Sequoia Pharmaceuticals
Founded Year
2002Stage
Series C | AliveTotal Raised
$57MValuation
$0000Last Raised
$35M | 16 yrs agoAbout Sequoia Pharmaceuticals
Sequoia Pharmaceuticals, Inc. is engaged in the discovery and development of antiviral therapeutics, with a focus on developing new treatments for drug-resistant infectious diseases such as HIV/AIDS and HCV-induced hepatitis. Sequoia Pharmaceuticals is located in Gaithersburg, Md.
Missing: Sequoia Pharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Sequoia Pharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Sequoia Pharmaceuticals
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Sequoia Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.
Biopharma Tech
838 items
Sequoia Pharmaceuticals Patents
Sequoia Pharmaceuticals has filed 19 patents.
The 3 most popular patent topics include:
- Abnormal psychology
- Antidepressants
- Antineoplastic drugs
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
1/11/2016 | 12/26/2017 | Hepatotoxins, Pharmacokinetics, Enzymes, Metabolism, Immunology | Grant |
Application Date | 1/11/2016 |
|---|---|
Grant Date | 12/26/2017 |
Title | |
Related Topics | Hepatotoxins, Pharmacokinetics, Enzymes, Metabolism, Immunology |
Status | Grant |
Latest Sequoia Pharmaceuticals News
Feb 11, 2011
After publicly chastisting the pharmaceutical industry for failing to partipicate in the Medicines Patent Pool, which is an initiative designed to streamline patent licensing for producing generics of patented HIV neds and lower prices in poor countries, several drugmakers are now holding talks about licensing arrangements. Among those in negotiations are Gilead Sciences, Sequoia Pharmaceuticals and ViiV Healthcare, a joint venture between Pfizer and GlaxoSmithKline, according to a statement from MPP, which adds that Roche is about to do the same. Non-committal replies, however, were received from Bristol-Myers Squibb, Abbott Laboratories and Boehringer-Ingelheim, while Merck rejected any arrangement. The responses come after MPP, which received a boost when the National Institutes for Health licensed a med to the organiziation (see here), released letters written to drugmakers - big and small - that make HIV/AIDS meds and upbraided them for failing to participate. The MPP then asked for replies by January 31 (you can read the correspondence here). Perhaps the big surprise, so far, is that ViiV has agreed to negotiate, given that Glaxo ceo Andrew Witty has previously indicated the venture would likely pursue other ways to provide HIV meds to poor countries. At the same time, Johnson & Johnson’s Tibotec unit has not agreed to negotiate and recently struck a separate licensing deal that some interpreted as a way to undermine the MPP (read this). "This represents great progress in pioneering a model that works for companies and for patients who need access to new and better medicines,” Ellen 't Hoen, executive director of the Medicines Patent Pool, says in a statement. “But we need other patent holders to engage with the Pool, too. It is only through conversation that we can work through differences and achieve critical public health goals.â
Sequoia Pharmaceuticals Frequently Asked Questions (FAQ)
When was Sequoia Pharmaceuticals founded?
Sequoia Pharmaceuticals was founded in 2002.
Where is Sequoia Pharmaceuticals's headquarters?
Sequoia Pharmaceuticals's headquarters is located at 401 Professional Drive, Gaithersburg.
What is Sequoia Pharmaceuticals's latest funding round?
Sequoia Pharmaceuticals's latest funding round is Series C.
How much did Sequoia Pharmaceuticals raise?
Sequoia Pharmaceuticals raised a total of $57M.
Who are the investors of Sequoia Pharmaceuticals?
Investors of Sequoia Pharmaceuticals include MedImmune Ventures, Aberdare Ventures, Wellcome Trust, Sofinnova Partners and Welcome Trust.
Who are Sequoia Pharmaceuticals's competitors?
Competitors of Sequoia Pharmaceuticals include BlueWillow Biologics, Aquinox Pharmaceuticals, Rhythm Pharmaceuticals, Eiger BioPharmaceuticals, VentiRx Pharmaceuticals and 12 more.
Compare Sequoia Pharmaceuticals to Competitors
Aderis Pharmaceuticals, formerly Discovery Therapeutics, develops and commercializes small molecule, receptor-specific therapeutics for the treatment of central nervous system, cardiovascular and renal diseases.
Avidimer Therapeutics is engaged in the discovery and development of therapeutics for inflammatory diseases
Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.
Calyx Therapeutics is a pharmaceutical company focusing on oral therapies for diabetes and inflammatory diseases. Calyx utilizes natural plant extracts with demonstrated clinical activity in humans as the source of its discovery efforts. The company isolates the biologically active molecule, determines its chemical structure, and aims to develop small molecule analogs. This process aims to reduce the time and investment required to take lead molecules into preclinical and clinical testing.
KeyNeurotek Pharmaceuticals is a clinical stage small molecule company focused on autoimmune and CNS diseases.
The focus of Savine Therapeutics is to develop and commercialise vaccines for prevention and treatment of diseases using it's Scrambled Antigen Vaccine (SAVINE) technology. The technology was invented by researchers in the John Curtin School of Medical Research at the Australian National University. Per the company, it enables production of vaccines suitable for a broad range of serious worldwide infectious diseases and cancers. See www.savine.com
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.